OBJECTIVE: The slit homologue 2 (SLIT2) gene is a tumour suppressor gene. This study investigated the methylation status of the SLIT2 promoter in women with ovarian cancer in terms of identifying whether this might aid the early diagnosis of ovarian cancer. METHODS: Using methylation-specific polymerase chain reaction analysis, the methylation status of the SLIT2 promoter was measured in tumour tissue and serum samples from 36 patients with ovarian cancer and in matched serum samples from 25 controls without cancer. RESULTS: Aberrant methylation of the SLIT2 promoter was present in ovarian tissue from 29/36 (80.6%) ovarian cancer patients, but not in the 25 healthy controls. Among the cases with hypermethylation in their ovarian tissue, 27/29 (93.1%) of the case-matched serum DNA samples, including all four cases of early-stage ovarian cancer, showed hypermethylation of the SLIT2 promoter. CONCLUSIONS: Hypermethylation of the SLIT2 promoter may be a relatively early event in ovarian cancer; thus, its detection may be an effective approach to improve early diagnosis.
Introduction
Ovarian cancer is the leading cause of mortality among malignancies of the reproductive system in women. 1, 2 Over 70% of patients with ovarian cancer are at an advanced stage of disease at the time of diagnosis and the overall 5-year survival rate is approximately 30%. 1 Thus, early diagnosis is crucial for effective treatment and a favourable prognosis. 2 The promoter regions of many tumour suppressor genes are often methylated, which might provide a useful target in the detection of early-stage cancer.
The slit homologue 2 (SLIT2) gene is a tumour suppressor gene that has been found to affect tumourigenesis, invasion, metastasis and the prognosis of various cancers. 3 -7 The SLIT2 gene maps to chromosome 4p15.2 and consists of four tandem leucine-rich repeats, seven epidermal growth factor-like repeats, an agrin-laminin-perlecan-slit conserved space motif and a cystine knot. 8 A reduction in slit-2 protein levels due to hypermethylation of the SLIT2 promoter has been observed in tissue samples from numerous types of cancer, including lung, 5 colorectal, 9 R Dong, J Yu, H Pu et al. SLIT2 promoter methylation in ovarian cancer hepatocellular, 10 cervical 11 and breast. 12 Hypermethylation of promoter DNA in the serum of cancer patients has also been demonstrated. 13 -15 It seems, therefore, that there is frequent hypermethylation of the SLIT2 promoter in the serum DNA from women with ovarian cancer and this may be a promising new approach to aid the early diagnosis of this disease.
The present study investigated the methylation status of the SLIT2 gene promoter in ovarian cancer tissues and serum samples from women with ovarian cancer compared with case-matched serum samples from women without ovarian cancer.
Patients and methods

STUDY POPULATION
Patients with ovarian cancer attending the Department of Obstetrics and Gynaecology, The Fourth People's Hospital of Wuxi (Wuxi, Jiangsu Province, China) between June 2010 and May 2011 were recruited for this prospective study. Healthy women attending the hospital for routine check-up, who had neither an ovarian lesion nor a history of malignancy, were recruited as a control group.
The study protocol was approved by the Institutional Review Board of The Fourth People's Hospital of Wuxi and verbal informed consent was obtained from all participants.
SAMPLE COLLECTION
Primary ovarian tumour tissue was collected, from the patient group during or soon after surgery, immediately frozen in liquid nitrogen and stored at -80°C. The tissue samples were examined pathologically and patients were classified and graded according to the criteria of the International Federation of Gynaecology and Obstetrics (FIGO, http://www.figo.org/). Whole blood samples (3 ml) were also obtained, prior to any treatment, from both the patients and from the control group. The samples were then left at room temperature for 2 h to coagulate, centrifuged at 3000 g for 10 min and the serum was removed and stored at -80°C. All tissue and blood samples were taken at the beginning of the study.
BISULPHITE MODIFICATION OF DNA AND METHYLATION-SPECIFIC PCR
Total genomic DNA was prepared according to standard phenol/chloroform extraction procedures. In brief, 25 mg of tumour tissue or 500 µl of serum was digested with 20 µl proteinase K (20 mg/ml) overnight at room temperature. The DNA extraction procedure was then carried out twice using phenol/ chloroform, precipitated with 100% ethanol and dissolved in 10 mM Tris-HCl (pH 7.8) / 1 mM ethylenediaminetetra-acetic acid (pH 8.0).
Then, 1 µg of DNA from tumour and serum samples was bisulphite modified using the CpGenome™ DNA modification kit (Chemicon ® International, Temecula, CA, USA), according to the manufacturer's instructions. The modified DNA was subjected to methylation-specific polymerase chain reaction (PCR) as described previously. 16 Primer sequences and conditions for the methylation-specific PCR were as reported previously. 9 The PCR reaction was carried out using ZymoTaq™ DNA polymerase (Zymo Research, Irvine, CA, USA), following the manufacturer's instructions, in a thermal cycler (BD Biosciences, Hercules, CA, USA). The PCR products were separated using 2% agarose gels and visualized using ethidium bromide staining and ultraviolet light.
DETECTION OF CA-125 PROTEIN
The level of cancer antigen 125 (CA-125) in SLIT2 promoter methylation in ovarian cancer serum was tested using an enzyme-linked immunosorbent assay kit (Yaji Biotechnology Company, Shanghai, China), following the manufacturer's instructions.
STATISTICAL ANALYSES
All statistical analyses were carried out using SPSS ® statistical software, version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Student's t-test was used to test for difference in age between the two groups. Fisher's exact test was used to test the association between the methylation status of the SLIT2 promoter and clinicopathological characteristics. A Pvalue < 0.05 was considered to be statistically significant.
Results
Ovarian cancer tissues and blood samples from 36 female patients with ovarian cancer (aged 44 -78 years; median 63.8 years) were available for analysis. Blood samples were available from 25 control subjects (aged 48 -75 years; median 62.1 years). There was no statistically significant difference in age between the two groups.
Aberrant promoter methylation (hypermethylation) of the SLIT2 gene was detected in ovarian tissue samples from 29/36 (80.6%) women with ovarian cancer compared with none of the 25 serum samples from healthy controls (P < 0.001) ( Table 1) . Three representative cases are shown in Fig. 1 .
Promoter methylation (hypermethylation) in the case-matched serum DNA samples was detected in 27/29 (93.1%) of the patients who were positive for hypermethylation of the SLIT2 promoter in their ovarian tumour tissue ( Table 1 ). The seven patients who were negative for SLIT2 promoter hypermethylation in their ovarian tumour tissue were also negative for hypermethylation in their serum DNA samples.
No statistically significant relationship was observed between hypermethylation of the SLIT2 promoter and age, FIGO clinical stage, pathological status (i.e. serous, endometrioid or mucinous), or CA-125 levels ( Table 1) . Investigation of the association between methylation status of the SLIT2 promoter and clinicopathological characteristics revealed that, in the patient group, four cases had early-stage cancer (three at stage I [cases 1, 22 and 30] and one at stage II [case 17]) and all these four cases showed SLIT2 hypermethylation in both ovarian tissue and serum samples.
Discussion
The methylation of DNA is an enzymatic process that often occurs near CpG islands, which are areas of the genome with a high frequency of cytosine and guanine bases often found around gene promoters. 17 Research has shown that promoter hypermethylation can lead to the downregulation of tumour suppressor genes, resulting in their inactivation and a reduced ability to suppress malignances. 18 -21 Studies have demonstrated the presence of gene promoter methylation in the serum DNA of cancer patients, 22 -24 providing a potential noninvasive method to investigate whether or not SLIT2 is methylated.
Hypermethylation of the SLIT2 promoter has been frequently observed in ovarian cancer tissue, but rarely in normal ovaries. 25 This indicates that hypermethylation of the SLIT2 promoter might play an important role in ovarian cancer. Thus, the present study evaluated the methylation status of the SLIT2 promoter in serum from women with ovarian cancer and explored the relationship between SLIT2 promoter hypermethylation and clinicopathological characteristics in these patients.
Although ovarian cancer is the most fatal SLIT2 promoter methylation in ovarian cancer malignancy of the female reproductive system worldwide, 1 diagnostic tests are generally invasive. The present study showed hypermethylation of the SLIT2 promoter in 80.6% of ovarian cancer tissue samples and 93.1% of case-matched serum samples. Hypermethylation of the SLIT2 promoter was detected in all four cases of early stage ovarian cancer, suggesting that analysis of the hypermethylation status of the SLIT2 promoter may provide an improved approach for the early diagnosis of ovarian cancer compared with current methods. That patients who had hypermethylation of the SLIT2 promoter in their ovarian cancer tissue also frequently had hypermethylation of the SLIT2 promoter in their serum DNA, suggests that serological analysis may provide a less invasive method for the early diagnosis of ovarian cancer compared with current methods. The present study did not detect any association between hypermethylation of the SLIT2 promoter and clinicopathological characteristics such as age, pathological status or CA-125 levels. Only a small number of patients were investigated, thus further studies with larger experimental groups are needed to confirm the validity of using SLIT2 as a marker for the early diagnosis of ovarian cancer.
